AcquisitionFinTech
Bausch Health Companies Inc. acquired XIIDRA ®
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Bausch Health Companies Inc. -> XIIDRA ® · $1.4 billion
Under the terms of the agreement, Bausch + Lomb, through an affiliate, acquired XIIDRA ® and the other ophthalmology assets from Novartis for up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations of
Open source record (SEC) ↗